Anastasia Vyacheslavovna Osokina
Anastasia Vyacheslavovna Osokina has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Ol'Ga Leonidovna Barbarash
Federal State Budgetary Scientific Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Academician L.S. Barbarash Boulevard, 6, Kemerovo 650002, Russia
17 shared publications - Victoria N. Karetnikova
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia
14 shared publications - Olga M. Polikutina
Research Institute for Complex Issues of Cardiovascular Diseases
10 shared publications - Olga V. Gruzdeva
Federal State Budgetary Scientific Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Academician L.S. Barbarash Boulevard, 6, Kemerovo 650002, Russia
9 shared publications - Anna V. Ivanova
Research Institute for Complex Issues of Cardiovascular Diseases
6 shared publications - Aleksey Nikolaevich Sumin
Federal State Budgetary Scientific Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Academician L.S. Barbarash Boulevard, 6, Kemerovo 650002, Russia
5 shared publications
Latest Publications
- Open Access
- 25 December 2023
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 12 (4) , 7-19
TYPE 2 MYOCARDIAL INFARCTION: MODERN DIAGNOSTIC TECHNIQUES AND TREATMENT
HighlightsPatients with type 2 myocardial infarction have a more favorable course of the disease in the long-term postinfarction period compared with patients with type 1 myocardial infarction. We have determined the differences in clinical and anamnestic characteristics of patients with type 1 and type 2 MI. AbstractAim. To determine the prevalence of patients with type 2 myocardial infarction (MI) and their features in clinical practice.Methods. The prospective study involved 204 patients with acute coronary syndrome (ACS). The inclusion criteria were as follows: diagnosed ACS at admission followed by a confirmed MI during the inpatient period according to the Fourth Universal definition of MI. The following parameters were analyzed: anthropometric parameters, clinical and anamnestic characteristics, results of laboratory tests, biochemical markers of myocardial necrosis, results of instrumental diagnostics and coronary angiography. A follow-up telephone survey was carried out a year after ACS, noting the following endpoints: repeated coronary events, death, repeated hospitalizations, adherence to medical recommendations, medication taken by the patient.Results. Type 2 MI was diagnosed in 22 (10.8%) patients. The results of coronary angiography revealed either the absence of coronary artery (CA) stenosis or the presence of stenosis of less than 50% without indications of thrombosis in 16 (72.7%) of those patients. Chronic total occlusion of a non-infarct-related artery was found in 6 (27.3%) patients. Patients with type 2 MI were comparable in age with patients with type 1 MI. The group of patients with type 2 MI included more women (p = 0.029), fewer smokers (p = 0.037) and more cases of atrial fibrillation (AF) (p = 0.003) compared to patients with type 1 MI. The factors that were associated with type 2 MI were as follows: sinus tachycardia in 3 (13.6%) patients, paroxysmal atrial flutter or AF with ventricular tachysystole in 4 patients (18.2%).Conclusion. Patients with type 1 MI presented with a less favorable course of the disease: we noted higher number of recurrent MI and deaths one year after the index event compared with patients with type 2 MI. The group of patients with type 2 MI consisted mostly of women, fewer smokers and patients with dyslipidemia, as well as a more frequent indication of AF compared with patients with type 1 MI.
- 25 December 2023
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 12 (4) , 7-19
Open AccessTYPE 2 MYOCARDIAL INFARCTION: MODERN DIAGNOSTIC TECHNIQUES AND TREATMENT
HighlightsPatients with type 2 myocardial infarction have a more favorable course of the disease in the long-term postinfarction period compared with patients with type 1 myocardial infarction. We have determined the differences in clinical and anamnestic characteristics of patients with type 1 and type 2 MI. AbstractAim. To determine the prevalence of patients with type 2 myocardial infarction (MI) and their features in clinical practice.Methods. The prospective study involved 204 patients with acute coronary syndrome (ACS). The inclusion criteria were as follows: diagnosed ACS at admission followed by a confirmed MI during the inpatient period according to the Fourth Universal definition of MI. The following parameters were analyzed: anthropometric parameters, clinical and anamnestic characteristics, results of laboratory tests, biochemical markers of myocardial necrosis, results of instrumental diagnostics and coronary angiography. A follow-up telephone survey was carried out a year after ACS, noting the following endpoints: repeated coronary events, death, repeated hospitalizations, adherence to medical recommendations, medication taken by the patient.Results. Type 2 MI was diagnosed in 22 (10.8%) patients. The results of coronary angiography revealed either the absence of coronary artery (CA) stenosis or the presence of stenosis of less than 50% without indications of thrombosis in 16 (72.7%) of those patients. Chronic total occlusion of a non-infarct-related artery was found in 6 (27.3%) patients. Patients with type 2 MI were comparable in age with patients with type 1 MI. The group of patients with type 2 MI included more women (p = 0.029), fewer smokers (p = 0.037) and more cases of atrial fibrillation (AF) (p = 0.003) compared to patients with type 1 MI. The factors that were associated with type 2 MI were as follows: sinus tachycardia in 3 (13.6%) patients, paroxysmal atrial flutter or AF with ventricular tachysystole in 4 patients (18.2%).Conclusion. Patients with type 1 MI presented with a less favorable course of the disease: we noted higher number of recurrent MI and deaths one year after the index event compared with patients with type 2 MI. The group of patients with type 2 MI consisted mostly of women, fewer smokers and patients with dyslipidemia, as well as a more frequent indication of AF compared with patients with type 1 MI.
- Open Access
- 5 November 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (11) , 2977
The Role of Insulin Resistance in the Development of Complications after Coronary Artery Bypass Grafting in Patients with Coronary Artery Disease
The aim of the study was to investigate the effect of carbohydrate metabolism disorders and insulin resistance indices on the immediate results of coronary artery bypass grafting (CABG). Method. Patients with coronary artery disease who underwent CABG (n = 383) were examined to determine glycemic status, free fatty acid and fasting insulin levels, and insulin resistance indices (Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), McAuley index, Quantitative Insulin Sensitivity Check Index (QUICKI), Revised-QUICKI). Patients were assessed for the development of perioperative complications and their length of stay in the hospital. Two groups were formed: group 1, patients with a combined endpoint (CEP, any complication and/or duration of hospital stay >10 days), n = 291; and group 2 (n = 92) without a CEP. Perioperative characteristics were analyzed, and predictors of hospital complications and prolonged hospital stay were evaluated. Results. Patients in the CEP group were older, and there were more women among them (p = 0.003). Additionally, in this group, there were more patients with diabetes mellitus (37.5% vs 17.4%, p < 0.001), obesity (p < 0.001), and a higher percentage of combined operations (p = 0.007). In the group with a CEP, the levels of glucose (p = 0.031), glycated hemoglobin (p = 0.009), and free fatty acids (p = 0.007) and the Revised-QUICKI (p = 0.020) were higher than in the group without complications. In a regression analysis, the independent predictors of complications were combined operations (p = 0.016) and the predictors of a long hospital stay (>14 days) were female gender, the left atrium size, and diabetes mellitus (p < 0.001). The predictors of a composite endpoint included female gender, age, the left atrium size, and free fatty acid levels (p < 0.001). Conclusions: In the group with in-hospital complications after CABG, not only was the presence of diabetes mellitus more often detected, but there were also higher levels of free fatty acids and a higher Revised-QUICKI. Therefore, additional assessments of insulin resistance and free fatty acid levels are advisable in patients before CABG.
- 5 November 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (11) , 2977
Open AccessThe Role of Insulin Resistance in the Development of Complications after Coronary Artery Bypass Grafting in Patients with Coronary Artery Disease
The aim of the study was to investigate the effect of carbohydrate metabolism disorders and insulin resistance indices on the immediate results of coronary artery bypass grafting (CABG). Method. Patients with coronary artery disease who underwent CABG (n = 383) were examined to determine glycemic status, free fatty acid and fasting insulin levels, and insulin resistance indices (Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), McAuley index, Quantitative Insulin Sensitivity Check Index (QUICKI), Revised-QUICKI). Patients were assessed for the development of perioperative complications and their length of stay in the hospital. Two groups were formed: group 1, patients with a combined endpoint (CEP, any complication and/or duration of hospital stay >10 days), n = 291; and group 2 (n = 92) without a CEP. Perioperative characteristics were analyzed, and predictors of hospital complications and prolonged hospital stay were evaluated. Results. Patients in the CEP group were older, and there were more women among them (p = 0.003). Additionally, in this group, there were more patients with diabetes mellitus (37.5% vs 17.4%, p < 0.001), obesity (p < 0.001), and a higher percentage of combined operations (p = 0.007). In the group with a CEP, the levels of glucose (p = 0.031), glycated hemoglobin (p = 0.009), and free fatty acids (p = 0.007) and the Revised-QUICKI (p = 0.020) were higher than in the group without complications. In a regression analysis, the independent predictors of complications were combined operations (p = 0.016) and the predictors of a long hospital stay (>14 days) were female gender, the left atrium size, and diabetes mellitus (p < 0.001). The predictors of a composite endpoint included female gender, age, the left atrium size, and free fatty acid levels (p < 0.001). Conclusions: In the group with in-hospital complications after CABG, not only was the presence of diabetes mellitus more often detected, but there were also higher levels of free fatty acids and a higher Revised-QUICKI. Therefore, additional assessments of insulin resistance and free fatty acid levels are advisable in patients before CABG.
- Open Access
- 10 September 2023
- Published by Irkutsk State Medical University in Baikal Medical Journal
- Vol. 2 (3) , 98-100-100
PREDICTORS OF HOSPITAL COMPLICATIONS AND PROLONGED HOSPITALIZATION IN BYPASS PATIENTS: THE ROLE OF FREE FATTY ACIDS AND INSULIN RESISTANCE INDICES
Введение. Часто нарушения углеводного обмена (сахарный диабет 2-го типа. предиабет) выявляются у пациентов с тяжелой ишемической болезнью сердца, готовящихся к плановому коронарному шунтированию. Инсулинорезистентность может иметь место даже при отсутствии манифестных нарушений углеводного обмена и обладать собственным влиянием на течение ИБС. В отношении прогноза коронарного шунтирования роль инсулинорезистентности четко не определена, имеются единичные сообщения о связи расчетных индексов инсулинорезистенстности и свободных жирных кислот с числом послеоперационных осложнений КШ Цель исследования. Изучить влияние нарушений углеводного обмена и показателей инсулинорезистентности на непосредственные результаты коронарного шунтирования (КШ). Материалы и методы. Включены 383 последовательных пациента, подвергшихся КШ в 2011-2012 году в НИИ КПССЗ, у всех пациентов определены свободные жирные кислоты и инсулин натощак в плазме, рассчитаны индексы инсулинорезистентности HOMA-IR (Homeostasis Model Assessment of Insulin Resistance), QUICKI (Quantitative Insulin Sensitivity Chek Index) и Revised-QUICKI, McAuley. Проведен логистический регрессионный анализ для выявления предикторов комбинированной конечной точки «нахождение в стационаре после КШ >10 дней, либо наличие значимого осложнения». Были проанализированы периоперационные характеристики в двух группах группы: 1-я группа - пациенты с комбинированной конечной точкой (ККТ>10 дней), n=291, и 2-я группа (n=92) без ККТ. Результаты. В группе с ККТ медиана возраста была выше, а доля женщин составила 30% против 14,1% (р=0,003). У больных 1-й группы (с ККТ) был выше процент сахарного диабета 2-го типа (37,5% против 17,4%, рВыводы: В группе с осложненным послеоперационным периодом КШ было значимо больше женщин, пациентов с СД 2, и лиц с ожирением, отмечалась более высокая медиана свободных жирных кислот и индекса Revised-QUICKI. Среди независимых предикторов госпитальных осложнений или длительности пребывания в стационаре после КШ были уровень свободных жирных кислот и сахарный диабет 2 типа.
- 10 September 2023
- Published by Irkutsk State Medical University in Baikal Medical Journal
- Vol. 2 (3) , 98-100-100
Open AccessPREDICTORS OF HOSPITAL COMPLICATIONS AND PROLONGED HOSPITALIZATION IN BYPASS PATIENTS: THE ROLE OF FREE FATTY ACIDS AND INSULIN RESISTANCE INDICES
Введение. Часто нарушения углеводного обмена (сахарный диабет 2-го типа. предиабет) выявляются у пациентов с тяжелой ишемической болезнью сердца, готовящихся к плановому коронарному шунтированию. Инсулинорезистентность может иметь место даже при отсутствии манифестных нарушений углеводного обмена и обладать собственным влиянием на течение ИБС. В отношении прогноза коронарного шунтирования роль инсулинорезистентности четко не определена, имеются единичные сообщения о связи расчетных индексов инсулинорезистенстности и свободных жирных кислот с числом послеоперационных осложнений КШ Цель исследования. Изучить влияние нарушений углеводного обмена и показателей инсулинорезистентности на непосредственные результаты коронарного шунтирования (КШ). Материалы и методы. Включены 383 последовательных пациента, подвергшихся КШ в 2011-2012 году в НИИ КПССЗ, у всех пациентов определены свободные жирные кислоты и инсулин натощак в плазме, рассчитаны индексы инсулинорезистентности HOMA-IR (Homeostasis Model Assessment of Insulin Resistance), QUICKI (Quantitative Insulin Sensitivity Chek Index) и Revised-QUICKI, McAuley. Проведен логистический регрессионный анализ для выявления предикторов комбинированной конечной точки «нахождение в стационаре после КШ >10 дней, либо наличие значимого осложнения». Были проанализированы периоперационные характеристики в двух группах группы: 1-я группа - пациенты с комбинированной конечной точкой (ККТ>10 дней), n=291, и 2-я группа (n=92) без ККТ. Результаты. В группе с ККТ медиана возраста была выше, а доля женщин составила 30% против 14,1% (р=0,003). У больных 1-й группы (с ККТ) был выше процент сахарного диабета 2-го типа (37,5% против 17,4%, рВыводы: В группе с осложненным послеоперационным периодом КШ было значимо больше женщин, пациентов с СД 2, и лиц с ожирением, отмечалась более высокая медиана свободных жирных кислот и индекса Revised-QUICKI. Среди независимых предикторов госпитальных осложнений или длительности пребывания в стационаре после КШ были уровень свободных жирных кислот и сахарный диабет 2 типа.
- Open Access
- 28 April 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (2) , 126-133
Clinical Efficacy and Safety of Empagliflozin in Patients with Acute Heart Failure from the First Day of Hospitalization
Aim. Evaluation of the safety, clinical and hemodynamic effects of empagliflozin in patients with acute decompensated heart failure (ADHF) from the first day of hospitalization in the absence of signs of hemodynamic instability.Material and methods. A prospective, comparative, randomized study included 46 patients admitted to the hospital in connection with ADHF in the absence of signs of hemodynamic instability. Inclusion in the study and randomization to receive empagliflozin was carried out in the first 24 hours from the moment of admission to the hospital. The main group (n=23) from the first day of hospitalization and the entire subsequent follow-up period took empagliflozin at a daily dose of 10 and 25 mg (for patients with type 2 diabetes mellitus) in addition to basic therapy, the control group (n=23) received standard therapy without gliflozines. The observation period was 3 months and included 3 control points: 1st day of hospitalization, 7th-12th day, 3rd month of observation. Clinical, anamnestic and instrumental data were evaluated at all control points.Results. In the hospital period, by the 7th-12th day, only in the main group there was an improvement in all clinical indicators (p˂0.01), a decrease in the daily dose of the parenteral diuretic furosemide from 54 mg to 26 mg (p˂0.01), but it was more pronounced in the comparison group [from 141 (110; 160) to 110 (90; 120) mm Hg) compared to the main group [from 140 (120; 160) to 120 (110; 130) mm Hg]. According to echocardiography data in the main group, there was a decrease in the indexed volume of the right atrium, the end-systolic volume of the left ventricle (LV ESV) and systolic pressure in the pulmonary artery, an increase in the LV ejection fraction (LV EF) (p˂0.05). In the comparison group, only an increase in LV ESV was noted (p=0.04). The index of the indexed volume of the left atrium did not show significant dynamics in the main group (p=0.79), but showed a significant decrease in the 2nd and 3rd control points compared to the control group (p=0.01 and p=0.02). Complications, against the background of taking empagliflozin, were not noted: there were no episodes of hypotension (SBP˂90 mm Hg), hypoglycemia, acute kidney injury.Conclusion. The results obtained indicate the safety of empagliflozin in patients with ADHF, regardless of the status of carbohydrate metabolism and LV EF, as well as taking into account the clinical (more intense positive dynamics of clinical symptoms of ADHF) and hemodynamic (smooth decrease in SBP, increased diuretic effect) effects of empagliflozin, this drug should be considered as an effective and safe supplement to the main therapy from the first day of hospitalization in patients with stable hemodynamic parameters.
- 28 April 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (2) , 126-133
Open AccessClinical Efficacy and Safety of Empagliflozin in Patients with Acute Heart Failure from the First Day of Hospitalization
Aim. Evaluation of the safety, clinical and hemodynamic effects of empagliflozin in patients with acute decompensated heart failure (ADHF) from the first day of hospitalization in the absence of signs of hemodynamic instability.Material and methods. A prospective, comparative, randomized study included 46 patients admitted to the hospital in connection with ADHF in the absence of signs of hemodynamic instability. Inclusion in the study and randomization to receive empagliflozin was carried out in the first 24 hours from the moment of admission to the hospital. The main group (n=23) from the first day of hospitalization and the entire subsequent follow-up period took empagliflozin at a daily dose of 10 and 25 mg (for patients with type 2 diabetes mellitus) in addition to basic therapy, the control group (n=23) received standard therapy without gliflozines. The observation period was 3 months and included 3 control points: 1st day of hospitalization, 7th-12th day, 3rd month of observation. Clinical, anamnestic and instrumental data were evaluated at all control points.Results. In the hospital period, by the 7th-12th day, only in the main group there was an improvement in all clinical indicators (p˂0.01), a decrease in the daily dose of the parenteral diuretic furosemide from 54 mg to 26 mg (p˂0.01), but it was more pronounced in the comparison group [from 141 (110; 160) to 110 (90; 120) mm Hg) compared to the main group [from 140 (120; 160) to 120 (110; 130) mm Hg]. According to echocardiography data in the main group, there was a decrease in the indexed volume of the right atrium, the end-systolic volume of the left ventricle (LV ESV) and systolic pressure in the pulmonary artery, an increase in the LV ejection fraction (LV EF) (p˂0.05). In the comparison group, only an increase in LV ESV was noted (p=0.04). The index of the indexed volume of the left atrium did not show significant dynamics in the main group (p=0.79), but showed a significant decrease in the 2nd and 3rd control points compared to the control group (p=0.01 and p=0.02). Complications, against the background of taking empagliflozin, were not noted: there were no episodes of hypotension (SBP˂90 mm Hg), hypoglycemia, acute kidney injury.Conclusion. The results obtained indicate the safety of empagliflozin in patients with ADHF, regardless of the status of carbohydrate metabolism and LV EF, as well as taking into account the clinical (more intense positive dynamics of clinical symptoms of ADHF) and hemodynamic (smooth decrease in SBP, increased diuretic effect) effects of empagliflozin, this drug should be considered as an effective and safe supplement to the main therapy from the first day of hospitalization in patients with stable hemodynamic parameters.
- Open Access
- 11 April 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (3) , 3474
Type 2 myocardial infarction: the potential for early detection
Aim. To evaluate the potential of using factors associated with type 2 myocardial infarction (MI) for its early diagnosis.Material and methods. This prospective study included 204 patients diagnosed with acute coronary syndrome (ACS). At the time of admission, each patient underwent standard examinations for ACS patients. The 1-year stage consisted of telephone survey of patients on the course of long-term postinfarction period. There were following endpoints: death, recurrent coronary events and hospitalization.Result. Patients with type 2 MI accounted for 10,8% (n=22) of the entire analyzed sample. A model for prehospital diagnosis of probable type 2 MI has been developed. The model included clinical and history data that allow to suggest the type 2 MI course without invasive and laboratory studies. The model included signs (body mass index ≥35, kg/m2, atrial fibrillation+Killip I, hemoglobin Conclusion. A model of prehospital clinical assessment of MI risk has been developed for making a preliminary diagnosis and forming different patient streams at the admission stage for the final verification of the diagnosis.
- 11 April 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (3) , 3474
Open AccessType 2 myocardial infarction: the potential for early detection
Aim. To evaluate the potential of using factors associated with type 2 myocardial infarction (MI) for its early diagnosis.Material and methods. This prospective study included 204 patients diagnosed with acute coronary syndrome (ACS). At the time of admission, each patient underwent standard examinations for ACS patients. The 1-year stage consisted of telephone survey of patients on the course of long-term postinfarction period. There were following endpoints: death, recurrent coronary events and hospitalization.Result. Patients with type 2 MI accounted for 10,8% (n=22) of the entire analyzed sample. A model for prehospital diagnosis of probable type 2 MI has been developed. The model included clinical and history data that allow to suggest the type 2 MI course without invasive and laboratory studies. The model included signs (body mass index ≥35, kg/m2, atrial fibrillation+Killip I, hemoglobin Conclusion. A model of prehospital clinical assessment of MI risk has been developed for making a preliminary diagnosis and forming different patient streams at the admission stage for the final verification of the diagnosis.
- Open Access
- 4 January 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (12) , 5137
Role of glycemic control in elective percutaneous coronary interventions in patients with type 2 diabetes
Aim. To assess the association of glycemic control (achievement of an individual target glycated hemoglobin level) with the outcomes of elective percutaneous coronary interventions in patients with type 2 diabetes (T2D).Material and methods.This cohort observational study included 74 patients with a median age of 61 (57; 64) years. There were 49% of men with a previously established T2D, who had indications for elective primary percutaneous coronary intervention (PCI) for stable coronary artery disease. At inclusion in the study and after 1 month, the concentration of fasting blood glucose, glycated hemoglobin (HbA1c), fructosamine, and serum creatinine were determined. Plasma glucose levels were determined using the hexokinase method. HbA1clevel was determined by immunoturbidimetry on a Konelab 30i chemistry analyzer. The concentration of fructosamine was determined by the kinetic colorimetric assay on a Konelab 30i chemistry analyzer. Statistical processing was carried out using the Statistica 10.0 program from StatSoft, Inc. (USA).Results.At the time of enrollment, 31% of participants had not achieved the target glycated hemoglobin level against the background of nonoptimal hypoglycemic therapy in most cases. A total of 18 (25%) following adverse cardiovascular events were registered within 12 months after PCI: 11 (15%) patients developed acute coronary syndrome; among them, 6 (8%) patients had stent restenosis according to coronary angiography, 4 (6%) patients — progression of atherosclerosis, which required repeated PCI with stenting of another vessel, 2 (3%) patients — cerebrovascular accident, and 3 (4%) patients were hospitalized due to de compensated heart failure. According to multivariate logistic regression, only the HbA1clevel was a predictor of adverse outcomes during the year after PCI — a 1% increase in HbA1clevel increased the risk of adverse outcomes by 1,79 times (odds ratio, 1,79, 95% confidence interval, 1,06-3,02, p=0,028). Poor glycemic control 1 month before PCI increased the risk of cardiovascular events by 4,04 times over the next year, while non-target HbA1clevel immediately before PCI increased the risk of adverse outcomes by 4,7 times, and 5 months after PCI, by 7,34 times.Conclusion.The significance of non-target glycated hemoglobin level for adverse outcomes during the year after elective PCI against the background of T2D was established with an increase in the negative effect as long-term (after myocardial revascularization) maintenance of poor glycemic control.
- 4 January 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (12) , 5137
Open AccessRole of glycemic control in elective percutaneous coronary interventions in patients with type 2 diabetes
Aim. To assess the association of glycemic control (achievement of an individual target glycated hemoglobin level) with the outcomes of elective percutaneous coronary interventions in patients with type 2 diabetes (T2D).Material and methods.This cohort observational study included 74 patients with a median age of 61 (57; 64) years. There were 49% of men with a previously established T2D, who had indications for elective primary percutaneous coronary intervention (PCI) for stable coronary artery disease. At inclusion in the study and after 1 month, the concentration of fasting blood glucose, glycated hemoglobin (HbA1c), fructosamine, and serum creatinine were determined. Plasma glucose levels were determined using the hexokinase method. HbA1clevel was determined by immunoturbidimetry on a Konelab 30i chemistry analyzer. The concentration of fructosamine was determined by the kinetic colorimetric assay on a Konelab 30i chemistry analyzer. Statistical processing was carried out using the Statistica 10.0 program from StatSoft, Inc. (USA).Results.At the time of enrollment, 31% of participants had not achieved the target glycated hemoglobin level against the background of nonoptimal hypoglycemic therapy in most cases. A total of 18 (25%) following adverse cardiovascular events were registered within 12 months after PCI: 11 (15%) patients developed acute coronary syndrome; among them, 6 (8%) patients had stent restenosis according to coronary angiography, 4 (6%) patients — progression of atherosclerosis, which required repeated PCI with stenting of another vessel, 2 (3%) patients — cerebrovascular accident, and 3 (4%) patients were hospitalized due to de compensated heart failure. According to multivariate logistic regression, only the HbA1clevel was a predictor of adverse outcomes during the year after PCI — a 1% increase in HbA1clevel increased the risk of adverse outcomes by 1,79 times (odds ratio, 1,79, 95% confidence interval, 1,06-3,02, p=0,028). Poor glycemic control 1 month before PCI increased the risk of cardiovascular events by 4,04 times over the next year, while non-target HbA1clevel immediately before PCI increased the risk of adverse outcomes by 4,7 times, and 5 months after PCI, by 7,34 times.Conclusion.The significance of non-target glycated hemoglobin level for adverse outcomes during the year after elective PCI against the background of T2D was established with an increase in the negative effect as long-term (after myocardial revascularization) maintenance of poor glycemic control.
- Open Access
- 31 December 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (12) , 64-72
Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus
Aim To evaluate cardiometabolic effects of empagliflozin in patients with ischemic heart disease and type 2 diabetes mellitus (DM) following elective percutaneous coronary intervention (PCI). Materials and methods Patients meeting the inclusion/non-inclusion criteria were randomized into two groups of equal number using simple randomization with successively assigned numbers. Group 1 included 37 patients (18 men and 19 women) who gave their consent for the treatment with empagliflozin 10 mg/day in addition to their previous hypoglycemic therapy. The drug administration started one month prior to the elective PCI and continued for the next 11 months (treatment duration, 12 months). Group 2 (comparison group) consisted of age- and DM duration-matched patients (37 patients; 18 men and 19 women) who continued on their hypoglycemic therapy previously prescribed by endocrinologists during the entire study period. Before the study, 36.11 % patients of the empagliflozin group and 27.03 % of the comparison group had unsatisfactory glycemic control as shown by the level of glycated hemoglobin (HbA1c). Results At 6 and 12 months of the study, fasting glycemia and HbA1c were significantly lower in the empagliflozin treatment group. The groups were comparable by the incidence of adverse outcomes: 8 (22.24 %) patients in the empagliflozin group and 10 (27.04 %) patients in the comparison group (р=0.787). The 12-month empagliflozin treatment reduced total cholesterol (C) by 5.56 % (pConclusion The empagliflozin treatment for 30 days prior to and after elective PCI can enhance the effectiveness of myocardial revascularization due to the demonstrated beneficial cardiometabolic effects.
- 31 December 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (12) , 64-72
Open AccessCardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus
Aim To evaluate cardiometabolic effects of empagliflozin in patients with ischemic heart disease and type 2 diabetes mellitus (DM) following elective percutaneous coronary intervention (PCI). Materials and methods Patients meeting the inclusion/non-inclusion criteria were randomized into two groups of equal number using simple randomization with successively assigned numbers. Group 1 included 37 patients (18 men and 19 women) who gave their consent for the treatment with empagliflozin 10 mg/day in addition to their previous hypoglycemic therapy. The drug administration started one month prior to the elective PCI and continued for the next 11 months (treatment duration, 12 months). Group 2 (comparison group) consisted of age- and DM duration-matched patients (37 patients; 18 men and 19 women) who continued on their hypoglycemic therapy previously prescribed by endocrinologists during the entire study period. Before the study, 36.11 % patients of the empagliflozin group and 27.03 % of the comparison group had unsatisfactory glycemic control as shown by the level of glycated hemoglobin (HbA1c). Results At 6 and 12 months of the study, fasting glycemia and HbA1c were significantly lower in the empagliflozin treatment group. The groups were comparable by the incidence of adverse outcomes: 8 (22.24 %) patients in the empagliflozin group and 10 (27.04 %) patients in the comparison group (р=0.787). The 12-month empagliflozin treatment reduced total cholesterol (C) by 5.56 % (pConclusion The empagliflozin treatment for 30 days prior to and after elective PCI can enhance the effectiveness of myocardial revascularization due to the demonstrated beneficial cardiometabolic effects.
- Open Access
- 20 October 2022
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 37 (3) , 75-82
Type 2 myocardial infarction: Diagnostic features in real clinical practice
Purpose. To determine the incidence of type 2 myocardial infarction (MI) diagnosis (according to the Fourth Universal Definition) and the features of patient management in real clinical practice.Material and Methods. A retrospective study was performed by analyzing the case histories of 153 patients diagnosed with acute coronary syndrome (ACS). Inclusion criteria were the presence of ACS at admission followed by a confirmed diagnosis of MI during the hospital period according to the Fourth Universal Definition of MI and the age of patients > 18 years. Patients with severe comorbidities affecting the immediate prognosis and/or being an alternative to the diagnosis of MI were not included in the study.Results. The study showed that emergency coronary angiography was performed in 151 patients (98.7%). A decrease in the renal filtration function in the presence of chronic kidney disease was a contraindication to this study found in 1.3% of cases; 12 (8%) patients did not have coronary artery disease or had stenoses of less than 50%; these patients comprised the group of patients with type 2 MI. While analyzing the results of examination in patients with type 2 MI, ST segment elevation was detected in seven patients (58.4%) according to electrocardiography; ST segment depression was observed in one patient (8.3%); complete left bundle-branch block was found also in 1 case (8.3%), three individuals (25%) did not have any changes in the position of ST segment, but had a negative T wave. Analysis of possible etiological factors in the development of type 2 MI showed the presence of sinus tachycardia in two patients (16.7%), severe sinus bradycardia in one patient (8.3%), fl utter paroxysm and atrial fibrillation with tachysystole throughout the ventricles in two patients (16.7%), and history of atrial fibrillation in one patient (8.3%).Conclusion. Type 2 MI was diagnosed in 8% of patients with ACS with and without ST segment elevation where cardiac arrhythmias including sinus arrhythmias may be the potential etiological factors. Limited capabilities of assessing the stability of atherosclerotic plaque in the coronary artery including that in the presence of plaque thrombosis represent a significant negative factor for establishing diagnosis in routine clinical practice.
- 20 October 2022
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 37 (3) , 75-82
Open AccessType 2 myocardial infarction: Diagnostic features in real clinical practice
Purpose. To determine the incidence of type 2 myocardial infarction (MI) diagnosis (according to the Fourth Universal Definition) and the features of patient management in real clinical practice.Material and Methods. A retrospective study was performed by analyzing the case histories of 153 patients diagnosed with acute coronary syndrome (ACS). Inclusion criteria were the presence of ACS at admission followed by a confirmed diagnosis of MI during the hospital period according to the Fourth Universal Definition of MI and the age of patients > 18 years. Patients with severe comorbidities affecting the immediate prognosis and/or being an alternative to the diagnosis of MI were not included in the study.Results. The study showed that emergency coronary angiography was performed in 151 patients (98.7%). A decrease in the renal filtration function in the presence of chronic kidney disease was a contraindication to this study found in 1.3% of cases; 12 (8%) patients did not have coronary artery disease or had stenoses of less than 50%; these patients comprised the group of patients with type 2 MI. While analyzing the results of examination in patients with type 2 MI, ST segment elevation was detected in seven patients (58.4%) according to electrocardiography; ST segment depression was observed in one patient (8.3%); complete left bundle-branch block was found also in 1 case (8.3%), three individuals (25%) did not have any changes in the position of ST segment, but had a negative T wave. Analysis of possible etiological factors in the development of type 2 MI showed the presence of sinus tachycardia in two patients (16.7%), severe sinus bradycardia in one patient (8.3%), fl utter paroxysm and atrial fibrillation with tachysystole throughout the ventricles in two patients (16.7%), and history of atrial fibrillation in one patient (8.3%).Conclusion. Type 2 MI was diagnosed in 8% of patients with ACS with and without ST segment elevation where cardiac arrhythmias including sinus arrhythmias may be the potential etiological factors. Limited capabilities of assessing the stability of atherosclerotic plaque in the coronary artery including that in the presence of plaque thrombosis represent a significant negative factor for establishing diagnosis in routine clinical practice.
- Open Access
- 26 September 2021
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 6 (3) , 46-55
Serum markers of cardiac fibrosis suffering from heart failure with preserved left ventricular ejection fraction upon ST-segment elevation myocardial infarction
Aim. Currently, there is no method which accurately predicts an adverse outcome of heart failure with a preserved left ventricular ejection fraction (HFpEF) upon ST-segment elevation myocardial infarction (STEMI). Here we studied the prognostic significance of procollagen type I C-terminal propeptide (PICP) and procollagen type III N-terminal propeptide (PIIINP) in patients with post-STEMI HFpEF.Material and Methods. The study included 83 patients (60 men and 23 women) with post-STEMI HFpEF (left ventricular EF ≥ 50%) and 20 ageand gender-matched healthy controls. Serum concentrations of PICP and PIIINP were measured on the 1st day of hospitalization using enzyme-linked immunosorbent assay with the following calculation of PICP/PIIINP ratio.Results. Serum PICP and PIIINP on the 1st day of STEMI significantly (3.4-fold) exceeded the values of the control group and were as follows: PIIINP: 26.0 (18.9; 34.9) ng/mL (р = 0.047); PICP: 609.0 (583.0; 635.0) ng/mL (р = 0.049).Conclusion. Elevated values of procollagens indicate that cardiac fibrosis commences within the 24 hours after STEMI onset. The pivotal role of cardiac fibrosis in the formation of diastolic dysfunction suggests the usefulness of serum procollagens to predict the development of HFpEF in a long-term period upon STEMI.
- 26 September 2021
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 6 (3) , 46-55
Open AccessSerum markers of cardiac fibrosis suffering from heart failure with preserved left ventricular ejection fraction upon ST-segment elevation myocardial infarction
Aim. Currently, there is no method which accurately predicts an adverse outcome of heart failure with a preserved left ventricular ejection fraction (HFpEF) upon ST-segment elevation myocardial infarction (STEMI). Here we studied the prognostic significance of procollagen type I C-terminal propeptide (PICP) and procollagen type III N-terminal propeptide (PIIINP) in patients with post-STEMI HFpEF.Material and Methods. The study included 83 patients (60 men and 23 women) with post-STEMI HFpEF (left ventricular EF ≥ 50%) and 20 ageand gender-matched healthy controls. Serum concentrations of PICP and PIIINP were measured on the 1st day of hospitalization using enzyme-linked immunosorbent assay with the following calculation of PICP/PIIINP ratio.Results. Serum PICP and PIIINP on the 1st day of STEMI significantly (3.4-fold) exceeded the values of the control group and were as follows: PIIINP: 26.0 (18.9; 34.9) ng/mL (р = 0.047); PICP: 609.0 (583.0; 635.0) ng/mL (р = 0.049).Conclusion. Elevated values of procollagens indicate that cardiac fibrosis commences within the 24 hours after STEMI onset. The pivotal role of cardiac fibrosis in the formation of diastolic dysfunction suggests the usefulness of serum procollagens to predict the development of HFpEF in a long-term period upon STEMI.
- Open Access
- 17 August 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (8) , 802
Screening for Glucose Metabolism Disorders, Assessment the Disse Insulin Resistance Index and Hospital Prognosis of Coronary Artery Bypass Surgery
Objective: To study insulin resistance markers and their relationship with preoperative status and hospital complications of coronary artery bypass grafting (CABG) in patients with type 2 diabetes, prediabetes and normoglycemia. Methods: We included 383 consecutive patients who underwent CABG. Patients were divided into two groups—with carbohydrate metabolism disorders (CMD, n = 192) and without CMD (n = 191). Free fatty acids and fasting insulin in plasma were determined, and the Disse, QUICKI and revised QUICKI indices were calculated in all patients. Perioperative characteristics and postoperative complications were analyzed in these groups, and their relations with markers of insulin resistance. Results: Screening before CABG increased the number of patients with CMD from 25.3% to 50.1%. Incidence of postoperative stroke (p = 0.044), and hospital stay after CABG > 30 days (p = 0.014) was greater in CMD patients. Logistic regression analysis revealed that an increase in left atrial size, age, aortic clamping time, and decrease in Disse index were independently associated with hospital stay >10 days and/or perioperative complications. Conclusions: Screening for CMD before CABG increased the patient number with prediabetes and type 2 diabetes. In the CMD group, there were more frequent hospital complications. The Disse index was an independent predictor of long hospital stay and/or poor outcomes.
- 17 August 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (8) , 802
Open AccessScreening for Glucose Metabolism Disorders, Assessment the Disse Insulin Resistance Index and Hospital Prognosis of Coronary Artery Bypass Surgery
Objective: To study insulin resistance markers and their relationship with preoperative status and hospital complications of coronary artery bypass grafting (CABG) in patients with type 2 diabetes, prediabetes and normoglycemia. Methods: We included 383 consecutive patients who underwent CABG. Patients were divided into two groups—with carbohydrate metabolism disorders (CMD, n = 192) and without CMD (n = 191). Free fatty acids and fasting insulin in plasma were determined, and the Disse, QUICKI and revised QUICKI indices were calculated in all patients. Perioperative characteristics and postoperative complications were analyzed in these groups, and their relations with markers of insulin resistance. Results: Screening before CABG increased the number of patients with CMD from 25.3% to 50.1%. Incidence of postoperative stroke (p = 0.044), and hospital stay after CABG > 30 days (p = 0.014) was greater in CMD patients. Logistic regression analysis revealed that an increase in left atrial size, age, aortic clamping time, and decrease in Disse index were independently associated with hospital stay >10 days and/or perioperative complications. Conclusions: Screening for CMD before CABG increased the patient number with prediabetes and type 2 diabetes. In the CMD group, there were more frequent hospital complications. The Disse index was an independent predictor of long hospital stay and/or poor outcomes.